Baktrim

Baktrim – (200 mg + 40 mg) /5 ml Oral suspension

Baktrim contains the active substances sulfamethoxazole and trimethoprim. Sulfamethoxazole (SMZ) inhibits the bacterial synthesis of dihydrofolic acid, by competing with p-aminobenzoic acid.
Trimethoprim (TMP) inhibits the production of tetrahydrofolic acid, by inhibiting the dihydrofolate reductase enzyme. This combination blocks two consecutive phases of the bacterial biosynthesis of essential nucleic acids and proteins and usually exerts a bactericidal action.

Baktrim paedriatic oral suspension is indicated in:
• respiratory tract infections such as: pneumonia by Pneumocystis carinii, acute exacerbation of chronic bronchitis, bronchiectasis, lung abscess, bronchopneumonia, sinusitis and otitis media;
• genitourinary tract infections such as: urethritis, acute and chronic cystitis, pyelitis, pyelonephritis, prosthatitis, gonorrhea;
• gastrointestinal tract infections, caused by Salmonella typhi and paratyphi etc., such as dysentery, traveler’s diarrhea, typhoid and paratyphoid fever, cholera;
• skin infections; in bacterial complications of some pediatric infectious diseases, such as: measles, scarlatina, pertussis; chronic and acute osteomyelitis, acute brucellosis;
• toxoplasmosis and nocardiosis.
Except pneumonia by Pneumocystis carinii where it is a first-line treatment, toxoplasmosis and nocardiosis, in the other indications such as in the exacerbations of chronic bronchitis, urinary tract infections and in otitis media in children, the use of Baktrim should be carefully considered, only when there is a bacteriological evidence for sensibility to this drug and a strong reason to use it and not a single antibacterial.